Business Context and Reporting Period
This Form 8-K filing by Protagonist Therapeutics, Inc. (PTGX) reports significant executive leadership changes effective May 7, 2019. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newark, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure: Richard S. Shames, M.D., transitioned from Chief Medical Officer to clinical advisor effective May 7, 2019.
- Appointments: Samuel Saks, M.D., was appointed Chief Medical Officer (promoted from Chief Development Officer). Suneel Gupta, Ph.D., was appointed Chief Development Officer (promoted from Executive Vice President of Clinical Pharmacology and Clinical Operations).
- Severance: Dr. Shames received a separation agreement providing nine months of base salary and COBRA coverage. He will provide approximately 80 hours of transitional consulting at $250/hour through June 30, 2019. His equity awards ceased vesting on the separation date.
- Compensation Adjustments:
- Dr. Saks' annualized base salary increased to $150,000. He was awarded an option grant for 45,000 shares.
- Dr. Gupta's annualized base salary increased to $400,000.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business strategy. No specific risks or contingencies were disclosed in this report other than the standard implications of executive turnover.
Investor Verification Checklist
- Verify the impact of the leadership transition on the company's clinical development pipeline.
- Review the Separation Agreement (Exhibit 10.1) for details on non-compete or non-solicitation clauses.
- Confirm the vesting schedule and exercise price for Dr. Saks' 45,000 share option grant.
- Assess the total cash outflow for Dr. Shames' severance and consulting fees relative to the company's current cash position (data not in this filing).